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Abstract: Novel strategies are needed to address vaccine hesitancy (VH), which correlates with 
complementary and alternative medicine (CAM). In Switzerland, CAM providers play important 
roles in vaccine counseling of vaccine hesitant (VH) parents, and traditional vaccination messaging 
tends to overlook CAM provider perspectives. In the setting of a Swiss national research program 
on VH, our key strategy has been to work together closely with CAM providers. To assess the 
feasibility of generating educational human papillomavirus (HPV) vaccine materials that would 
interest VH healthcare providers (HCPs), we invited four CAM providers to co-author two HPV 
vaccine review articles for general practitioners. We conducted thematic analysis of CAM provider 
comments to identify patterns that could complement and improve vaccination messaging from 
CAM perspectives. We identified several themes and generated an inventory of CAM provider 
messaging recommendations related to language use, presentation of background information, 
nuanced statements regarding HPV vaccine efficacy and safety, and communication tools that 
would be important to VH HCPs. Contrary to our initial expectations, and in an inclusive, respectful 
atmosphere of open dialogue, we were able to productively finalize our manuscripts. In the opinion 
of the CAM co-authors, the manuscripts effectively considered the communication needs and 
perspectives of VH HCPs. Engaging with CAM providers appears to be a feasible and innovative 
avenue for providing vaccine information and designing communication tools aimed at VH 
healthcare providers.  
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1. Introduction 
In 2019, the World Health Organization (WHO) listed vaccine hesitancy (VH) as one of 10 major 
threats to global health [1]. Understanding VH remains a puzzling challenge for clinicians and public 
health authorities [2–4]. Strategies to address VH have included reinforcing traditional information 
approaches focused on improving knowledge [5], clinicians using presumptive rather than 
participatory communication styles [6], motivational interviewing [7], and vaccine mandates [8–10]. 
In response to the WHO’s announcement about the “threat” of VH, strategies to address VH are 
urgently needed. 
Studies show a complex association between complementary and alternative medicine (CAM) 
use and VH [11], with popular narratives typically decrying CAM users and providers as 
categorically anti-vaccine [12]. However, research conducted in the setting of our national research 
program on VH [13,14] has suggested that providers of CAM in Switzerland are not categorically 
anti-vaccine. They prefer providing individualized vaccination counseling, which includes taking 
time to understand parent vaccine wishes, involving parents in vaccine decisions, and taking their 
vaccine concerns seriously [15].  
Not only patients are vaccine hesitant; evidence now suggests the need to address VH among 
healthcare providers (HCPs) [16–18]. Based on repeated suggestions to us by Swiss CAM providers 
that VH HCPs are unlikely to even read review articles that employ the traditional communication 
approach that vaccines are safe and effective, we tested a strategy of listening to CAM providers’ 
perspectives and including them as co-authors in our review articles and communication tools for 
HPV vaccines. To our knowledge, CAM providers, who play an important role in vaccination 
counseling in Switzerland, have previously not been involved in similar collaborations. We 
hypothesized that, in order to reach VH HCPs, it is important to use nuanced language that considers 
particular vaccine concerns and communication needs. The endpoint of our collaboration was 
therefore to write HPV vaccine review articles together with CAM doctors so that VH HCPs would 
actually read them.  
Here we investigate whether an innovative approach to engaging with CAM providers is 
feasible and productive. The objective of this article is to provide detailed characterizations of the 
insights and lessons we learned from including four Swiss CAM doctor comments, with two as co-
authors, in two HPV vaccine review articles [19,20] written for Swiss general practitioners (both 
articles originally in German, one translated to French). Overall, our findings suggest that including 
CAM providers in the collaborative writing of vaccine review articles is a feasible, productive, and 
potentially promising approach to design communication tools for clinical practice in order to 
address VH.  
2. Methods 
In Switzerland, CAM use is prevalent among 25%–50% of the population [21,22], reimbursed 
through mandatory basic health insurance when provided by medical doctors with additional 
postgraduate training and certification in anthroposophic medicine, traditional Chinese 
medicine/acupuncture, phytotherapy, or homeopathy [23], and often provided by medical doctors 
who have undertaken additional CAM training [24]. According to the register of medical professions 
of the Swiss Federal Office of Public Health (FOPH), there are 1051 licensed medical doctors with 
additional accredited CAM training [25]. However, the number of licensed medical doctors who 
practice CAM or offer CAM services without full accreditation is likely higher. A representative study 
of pediatricians in Switzerland reported that 23% of pediatricians had attended CM training, but only 
8% had a federal certificate in one or more of these methods [26]. The same study found that 97% of 
pediatrician respondents reported patients and parents inquiring about CAM, 65% were interested 
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in pursuing CAM training, 16% provided CAM to their patients, and more than 50% used CAM for 
themselves or their families. 
Despite vaccination being on a voluntary basis and the popularity of CAM in the Swiss context, 
vaccination rates for childhood vaccinations are overall relatively high for most routine childhood 
vaccinations (i.e., 87%–93% nationally for 2 doses of mumps, measles, and rubella vaccine for 2-, 8-, 
and 16-year-olds) [27]. However, there is high variance in HPV vaccination coverage between the 
different Swiss cantons (states). Cantonal coverage ranges from 19% to 79% for two doses of the HPV 
vaccine among 16-year-old females, and estimates for males are not yet available [27]. HPV 
vaccination is the vaccination that has achieved lowest coverage nationally among those 
recommended in the national vaccination plan [27,28].  
We incorporated 4 trained CAM doctors’ comments and suggestions and included 2 of them as 
co-authors on 2 HPV vaccine review articles and communication tools that we wrote for general 
practitioners (GP) in Switzerland as the target audience [19,20]. One article was published, in both 
German and French, in Swiss Medical Forum, a peer-reviewed journal published by the Swiss 
Medical Association. In surveys, it has repeatedly been recorded as the most widely read continuing 
medical education journal in Switzerland, with 39,000 copies printed per issue [29]. The other article 
was published in German in Ars Medici, a popular Swiss family medicine journal, with 7500 copies 
printed per issue. Our goal was to write and frame review articles with CAM providers in order to 
craft messages about HPV vaccine which would be palatable also to VH HCPs while at the same time 
providing medically sound, evidence-based information. The intent of both articles was to generate 
tools for providers, including VH HCPs, to engage in high-quality HPV vaccine counseling, which 
has been demonstrated as an important factor when addressing patient VH [30–32]. 
In order to provide an inside look into the discussions with our CAM doctor co-authors, we 
assembled their suggestions and have subjected their comments to thematic analysis, a commonly 
used, pragmatic tool allowing researchers to identify and analyze patterns in qualitative data. We 
followed Braun and Clarke’s [33] suggestions regarding the 6 phases of thematic analysis: getting 
familiar with the data, generating initial codes, searching for themes, reviewing themes, defining and 
naming themes, and producing the report ([33], p. 87). We used the Framework Method [34] to 
structure our analyses and used MAXQDA software to code and organize our data into meaningful 
themes.  
The 4 reviewing CAM doctors included 2 pediatricians specialized in anthroposophic medicine, 
a general practitioner (GP) specialized in homeopathy, and a GP of integrative family medicine. We 
did not assume that they provided suggestions representative of all CAM providers, but we included 
their contributions with the hypothesis that university researchers and public health authorities could 
learn from CAM provider’s experiences and perspectives when generating medical review articles 
and communication tools and vice versa. Of note, B.W. is a chief of pediatrics of the most renowned 
Swiss hospital specializing in anthroposophic medicine, B.H. is a chief of the first center for 
integrative pediatrics at a Swiss public hospital, C.G. is an influential private family medicine 
practitioner, and G.E. is president of the Swiss association of homeopathic physicians and of UNION 
of associations of Swiss physicians of complementary medicine.  
3. Results 
Through analysis of four CAM doctor recommendations for two manuscripts, we identified 
several patterns, which allowed us to group data into five overarching themes related to language 
and terminology, HPV vaccine efficacy, safety, communication tools for clinical consultation, and 
other important points deserving elaboration. The themes are presented in detail in the Tables where 
we display the specific content of CAM doctor recommendations, how we coded various sub-themes, 
and if we included their recommendations in the final manuscripts.  
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3.1. Language and Terminology 
An overarching criticism was that the manuscripts appeared to be peddling pro-vaccination 
“propaganda”, which the CAM doctors argued would be unacceptable for VH HCPs. They 
hypothesized that prominent statements such as “HPV vaccine is safe and effective”, which already 
regularly appear in literature published by public health authorities and in medical guidelines [35], 
would lead VH HCPs to not even read the manuscripts. They recommended that we opt for nuances 
such as the vaccine “is considered” to be safe and effective. Other linguistic nuances included 
statements that were presented as proven facts, whereas there might be underlying uncertainty; they 
recommended we state, “most experts agree”, rather than “experts agree”.  
We did not follow recommendations to remove two statements that CAM doctors considered to 
be “pro-vaccine propaganda”, related to vaccine efficacy in reducing genital warts, and waiting to 
vaccinate until 2020 until data on vaccine efficacy in preventing cervical cancer would be available. 
All agreed to underline that HPV vaccine today is well documented to reduce the incidence of 
cervical dysplasia (Table 1).   
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Table 1. Language and terminology. 
Item Complementary and Alternative Medicine (CAM) Doctor Comments CAM Co-Author Recommendations That We Included in Revised Manuscripts 
CAM Co-Author Recommendations That We Did Not Include 
and Reasons for Not Including Them 
Title 
-The title (“HPV vaccine: Update 2018 for Clinical Practice”) is neutral and 
therefore acceptable. 
-When vaccine hesitant (VH) healthcare providers (HCPs) come across an article 
entitled “HPV vaccine: safe and effective”, [35] they are likely to not even read it 
because they will expect an excessively enthusiastic pro-vaccine article, the same 
“government propaganda” that they have seen over the past decades. 
-An advantage of your article in the eyes of VH HCPs will be that it is not 
written by authors affiliated with the Swiss Federal government. 
-In the title, mention: 
-The aim of the manuscript is to provide well-balanced 
vaccine information.  
-The individual nature of vaccine decisions. 
-If you consider the statement that HPV vaccine is “safe 
and effective” to be essential, at least think about the 
nuance that HPV vaccine “is considered” by the 
authorities to be safe and effective. 
 
Statements that are 
pro-vaccine 
propaganda 
-The CAM co-authors made comments on the following statements: 
“Genital warts have essentially disappeared in countries like Australia where 
high HPV vaccine coverage was achieved early on”. This might well be correct. 
However, it is propaganda because at the time of HPV vaccine introduction in 
Australia, this high level of vaccine efficacy was an unproven assumption. 
“Do not wait with recommending the vaccine to your patients until 2020, when 
data on prevention of cancer will be available”. This is correct.  
Today, however, this is “propaganda” because it is not yet known whether the 
vaccine prevents cervical cancer in addition to dysplasia. 
-Such statements are not needed. Concentrate on the 
good pro-vaccine arguments that your article already 
has assembled. 
-Present readers with the data that are available today so 
they can reach their own conclusions. 
-We did not remove this statement because we found the effect of 
HPV vaccine on genital warts to be relevant. 
-We did not remove the statement regarding data on cancer 
prevention by HPV vaccine becoming available in 2020 because it 
is factually accurate, and vaccinating against HPV will, in the 
meantime, lead to reductions of dysplasia cases. 
Use of the term 
“protection” 
-Do not use the term “protection” in an indiscriminate way. Sloppy use of 
language contributes to hesitancy towards vaccines and promotes the impression 
of “pro-vaccine propaganda”. 
-Be careful to use specific terms for specific concepts. For 
example, be attentive to separate the following potential 
correlates of protection: 
-Documented doses of vaccine. 
-Induction of antibodies. 
long-term protection against dysplasia and/or cancer. 
 
General language 
use 
-Your statement about “optimal” vaccine counseling makes us wonder about 
your intentions.  
-Is the goal to reach maximal vaccination coverage in the population? Or, is it, as 
CAM physicians will consider to be just as important, to help patients reach their 
personal, individually selected health and prevention goals? 
-Be attentive to the formulation of the following 
statements: 
-HPV “can cause”, rather than “causes”, cancer. 
-HPV vaccination of boys “may prevent”, rather than 
“prevents”, cancer. 
-Prevention of genital warts via HPV vaccine “may be”, 
instead of “is”, worthwhile. 
-Use the word “reservations”, rather than “concerns”, 
about the HPV vaccine. 
-The data “suggests”, rather than “is solid”, that HPV 
vaccines are safe. 
-“Most experts agree”, rather than “experts agree”, that 
HPV vaccines are safe. 
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3.2. Vaccine Efficacy 
The CAM doctors recommended we refine our discussion by highlighting that projections 
regarding vaccine efficacy to protect against anal and orophyngeal cancers were hypothetical at the 
time the articles were written in late 2017. Another item had to do with natural vs. vaccine-induced 
antibodies. They indicated that CAM providers are generally highly interested in the body’s ability 
to remove HPV and heal dysplasia after HPV acquisition by naturally induced immune responses. 
The CAM doctors agreed that vaccination induces HPV-specific antibodies much more reliably and 
at higher serum concentrations compared to natural infection, this being a salient argument in favor 
of HPV vaccine (Table 2). 
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Table 2. Vaccine Efficacy. 
Item CAM Doctor Comments CAM Co-Author Recommendations That We Included into Revised Manuscripts 
Protection against dysplasia 
vs. cancer 
-Data on vaccine protection against cervical cancer is not yet available 1. This is an important 
limitation to government vaccine enthusiasm. 
-Emphasize that published data only support protection against cervical dysplasia at 
present time and not against cancer. 
-Tell the readers when data on protection against cancer is expected. 
-Mention that no data yet exists to support vaccine efficacy against anal, 
oropharyngeal, and other cancers. 
-It is acceptable to state that experts expect vaccine to protect well also against anal 
and oropharyngeal cancer, even though data is not yet available. State this as a 
hypothesis. 
Protection against dysplasia 
should not be 
underestimated 
-It is helpful to mention that a diagnosis of cervical dysplasia can be associated with uncertainty 
and anxiety for many months. 
-However, do not let this create the impression that the vaccine is 100% effective in 
preventing dysplasia, which could lead to reduced enthusiasm for continuing to 
undergo dysplasia screening at regular intervals. 
-Rather, mention that HPV vaccine and dysplasia screening are complementary 
cancer prevention methods for the time being. 
Duration of vaccine 
protection 
-The duration of protection is an important component of high-quality HPV vaccine counseling. 
-Hesitancy towards HPV vaccine is in part related to the fact that it is unclear if booster doses 
will be necessary. 
-With only 13 years of experience with HPV vaccines, it seems premature to 
conclude that HPV protection is likely to last for at least 20 years. Use clear language 
about this, and provide references. 
-It seems premature to anticipate that vaccine protection will be lifelong. It is 
acceptable to state this as speculation. 
Natural vs. vaccine-induced 
antibodies 
-Your point that HPV vaccination induces HPV antibodies much more reliably, at higher serum 
concentration than “natural” HPV infection, and that vaccine-induced antibodies are protective 
against future infection with other HPV types, in contrast to naturally-induced antibodies, is 
important. 
-CAM providers are typically very interested in the concept that dysplasia is a sign that the body 
was unable to eliminate acute HPV infection, and that, in those with cancer, the body was unable 
to reverse dysplasia. 
-Making such a statement is helpful to reduce HPV vaccine hesitancy among VH 
HCPs. 
-Making this point is also important because it distinguishes immunity towards 
HPV from immunity towards measles, where naturally acquired immunity persists 
lifelong whereas vaccine-induced immunity may wane and cease to protect. 
-The concept of the possibility of non-clearance of HPV infections and dysplasia, 
respectively, are important arguments for the HPV vaccine. 
1 Note that these comments were made in late 2017 when cancer prevention data was not yet available. 
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3.3. Vaccine Safety 
CAM doctors pointed out that our manuscripts unnecessary highlighted the local adverse 
reactions to the HPV vaccine. They encouraged us to instead focus on HPV-vaccine specific safety 
issues, such as case reports of rare but serious illnesses following vaccination, without inciting fear. 
While commending our emphasis on large-scale epidemiological evidence, acknowledging such case 
reports, they argued, would appeal to the tendency of CAM providers to incorporate “experiential” 
knowledge and anecdotal evidence into their medical practices [15,36]. Finally, CAM co-authors 
agreed that we point to the collective benefit of the HPV vaccine outweighing the minimal potential 
risks (Table 3). 
Table 3. Vaccine Safety. 
Item CAM Doctor Comments CAM Co-Author Recommendations That We Included into Revised Manuscripts 
Local adverse 
effects of HPV 
vaccine 
-You extensively discuss local adverse reactions to 
HPV vaccine, even though they are no different 
from other vaccines (i.e., pain, swelling at injection 
site).  
-Do not let the discussion of local reactions create the 
impression that you are downplaying the importance of 
the long-term safety of HPV vaccine, which clearly is 
more important.  
Case reports of 
serious adverse 
events following 
HPV vaccination 
-There are case reports suggesting an association 
of HPV vaccine with auto-immune and other 
serious illnesses: The link between vaccines and 
their potential for triggering pre-existing 
autoimmunity is an exciting field of investigation 
and points to the individual immune response to 
any vaccine. 
-This is not unlike the well-known association of 
antibiotic treatment of otitis media with rare side 
effects (e.g., anaphylaxis to penicillin, clostridium 
difficile colitis). Nobody would put into doubt the 
need to use antibiotics, when they are indicated, 
due to safety concerns. 
Similarly, nobody would stop driving a car for 
safety reasons, even though there certainly are 
more deaths attributable to car accidents than to 
adverse vaccine effects. Being mindful about the 
rare possibility of a car accident likely leads to 
more careful driving. Being mindful about the rare 
possibility of a serious adverse vaccine reaction 
may lead to more careful medical care of HPV-
vaccinated persons. 
-Acknowledge the existence of case reports of rare but 
serious illnesses following HPV vaccination, without 
using fear. Giving these case reports some space will 
provide for a more well-balanced article and will be 
crucial to enhance the credibility and acceptability of 
your article to VH HCPs. 
-Even if they are, do not dismiss these case reports as 
irrelevant or inferior quality evidence. CAM providers 
are more likely than biomedical physicians to accept 
“experiential” types of evidence, such as personal 
experiences and individual case reports. Do not 
underestimate their importance. 
-These case reports should not be overly dramatized, as 
is currently the case in the media and via dramatic 
reports by overt anti-vaxxers. 
Large scale 
epidemiological 
data suggests no 
serious long-term 
harm of HPV 
vaccine 
-The overall statement that HPV vaccine is a safe 
vaccine is credible. 
-Most VH HCPs will agree that this large-scale 
epidemiological data is robust, high-quality 
evidence supporting the safety of HPV vaccine.  
WHO states that after 270 million doses of HPV 
vaccine administered, no signals of any serious 
vaccine adverse effects have emerged. This 
statement may be counterproductive and make 
VH HCPs more skeptical because these data have 
been collected, in part, by vaccine manufacturers. 
This reduces the trustworthiness of the data and, 
therefore, confidence in the safety of HPV 
vaccines. 
-Consider putting these 2 concepts back to back in the 
manuscript by first stating, “Rare case reports suggest 
possible associations of HPV vaccine with multiple 
sclerosis”. 
-Follow this sentence by pointing out that large 
epidemiological studies “were unable to confirm these 
associations”.  
-Mention that long-term safety data is in being collected, 
in part, by vaccine manufacturers. 
-Even large-scale epidemiological studies cannot rule 
out that in rare cases, the HPV vaccine can be harmful to 
an individual patient. Mention this. 
-Therefore, HPV vaccine communication needs to be 
appropriately balanced and circumspect, particularly 
because there is no epidemiological emergency to 
vaccinate the population. Mention this. 
Individual risk vs. 
collective benefit 
Safety is a crucial aspect of any preventive 
measure, particularly for the HPV vaccine because 
it is now recommended for the entire population 
of young men and women.  
-Mention that only a small fraction of vaccinated 
persons will individually benefit because HPV-
associated cancers are overall rare. 
Mention vaccine safety as an important consideration 
because if everybody benefits from HPV vaccination, it 
is an acceptable assumption that the benefits outweigh 
the potential side effects. This will make the manuscript 
more balanced and acceptable to VH HCP readers. 
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3.4. Vaccine Communication Tools for Clinical Consultation 
CAM doctors suggested we “inform patients about”, as opposed to “recommending” HPV 
vaccine. They also suggested that we prominently state that all vaccines remain voluntary in 
Switzerland and that trusting relationships can exist between patients and physicians regardless of 
patient vaccination decisions. Finally, they recommended that all patients be explicitly invited to 
voice concerns and ask questions about HPV vaccine, similar to informed consent prior to any 
operative procedure, even patients who state they wish to be vaccinated.  
While CAM doctors pointed to how physicians can feel uneasy when broaching sexual matters, 
particularly with younger adolescents, they suggested we should not “de-sexualize” HPV vaccine. 
We did not follow their suggestions to include the possibility of waiting to vaccinate adolescents until 
age 15-16 years (when they would be more amenable to informed HPV vaccine discussions and 
decisions), which would not adhere to official recommendations to vaccinate at age 11-14 years, prior 
to adolescents becoming sexually active. Similarly, we did not include the suggested possibility of 
administering HPV and hepatitis B vaccines at separate times so as to attribute potential adverse 
effects to each individual vaccine (Table 4).  
Table 4. Vaccine communication tools for clinical consultation. 
Item CAM Doctor Comments CAM Co-Author Recommendations That 
We Included into Revised Manuscripts 
CAM Co-Author 
Recommendations That 
We Did Not Include and 
Reasons for Not 
Including Them 
The decision to 
vaccinate or not 
to vaccinate 
-Your statement that physicians 
should “patiently” and 
“extensively” provide HPV vaccine 
information is good.  
-Your statement that physicians 
should “inform” about HPV vaccine 
is good, and preferable to 
“recommending” the vaccine. 
-For those who agreed to receive 
HPV vaccine, proceeding to 
vaccinating without providing the 
patient with information is 
problematic (vaccine consent should 
be treated like pre-operative 
informed consent) 
-Mention these points explicitly:  
-Vaccination remains voluntary in 
Switzerland. Doctors and patients are free in 
their decision to vaccinate or not. 
-Good health and a relationship of trust with 
physicians is possible for parents and 
adolescents with or without the HPV 
vaccine.  
-Patients have a right to be informed in a 
well-balanced, circumspect manner about 
HPV vaccine. 
-Physicians should accept and respect 
patients’ personal vaccination decisions. 
-Doctors should invite patients to voice their 
concerns and ask questions about HPV 
vaccine even if they want the vaccine and 
have no questions about it.  
  
Talking about 
sexual matters 
-Many physicians feel uneasy when 
discussing sexual matters. This is a 
main reason for poor HPV vaccine 
counseling and contributes to HPV 
vaccine hesitancy.  
-Discussion of sexual topics requires 
an adequate amount of time. 
-Discussion of sexual topics with 
young adolescents in the 
recommended target age range (11-
14 years old) makes physicians even 
more uneasy. 
-In general, vaccine counseling is 
inadequately reimbursed. 
-Placing the emphasis on dysplasia/cancer 
prevention rather than prevention of an STD 
is acceptable. But do not “de-sexualize” the 
HPV vaccine. This is incompatible with an 
informed HPV vaccine decision. 
-Emphasize that HPV vaccination does not 
obviate the need for “safer sex” measures.  
-At 15-16 years, adolescents typically are 
ready for safer sex counseling. Many CAM 
physicians consider that HPV vaccine should 
not be given at 11-14 years but rather a few 
years later. Mention this as a possibility.  
-We did not increase the 
HPV vaccine target age 
from 11–14 to 15–16 
years and retained the 
official recommendation: 
HPV vaccine is ideally 
administered prior to 
individuals becoming 
sexually active. 
Vaccine 
administration 
in conjunction 
with the 
hepatitis B 
vaccine 
-It is correct to state that the HPV 
vaccine can be given at the same 
time as the hepatitis B vaccine. 
-Some VH HCPs and CAM providers prefer 
to give HPV and hepatitis B vaccine at 
different times in order for them to be able to 
attribute potential safety issues to each 
individual vaccine. Mention this as a 
possibility.  
-We did not modify our 
statement because we 
did not find HPV and 
HBV vaccine safety 
concerns sufficient 
enough to warrant this 
type of discussion. 
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3.5. Additional Important Items 
The following points seemed particularly pertinent because they drew our attention to items 
that might appeal to all readers, not just VH HCPs. For example, CAM doctors’ comments called our 
attention to the value of explicitly describing the sequence of events following natural HPV infection 
in order to help build a case for the importance of primary prevention against initial HPV infection 
via vaccine. Since VH is typically vaccine-specific, they encouraged us to provide more specific 
information on HPV infection before discussing HPV vaccine, that we elaborate on HPV vaccination 
for young men (since the recent recommendation to vaccinate boys and young men were likely not 
yet well known), and that we mention the cost of HPV vaccine, including how Swiss vaccination 
programs are funded, and that HPV vaccines are more expensive than other vaccines, and therefore 
likely lucrative for pharmaceutical companies. Finally, they agreed on mentioning HPV herd 
immunity thresholds in order to underscore the vaccine’s public health relevance (Table 5). 
Table 5. Additional important items. 
Item CAM Doctor Comments CAM Co-Author Recommendations that We Included into Revised 
Manuscripts 
Background 
information on 
HPV infection 
-The manuscripts begin with pro-vaccine 
statements about the safety and efficacy of 
the HPV vaccine. This gives impression that 
the manuscript is “pro-vaccine propaganda” 
-A well-balanced article should begin with extensive background 
information on HPV infection (natural history, complications), rather 
than HPV vaccine 
-Mention and underline that:  
-The recommendation to vaccinate boys and young men is not yet 
well known among general practitioners, rather than stating that we 
“now we need to introduce the vaccine” in young men. 
-HPV infection is the most common sexually transmitted infection. 
-HPV infection is harmless (i.e., transient) in >90% of the cases. 
-Cancer is a rare complication of HPV infections. 
-There are known risk factors (i.e., unprotected sex, number of sex 
partners) that support individualized HPV vaccine counseling. 
-There is no antiviral therapy available. This is in fact a pro-vaccine 
argument. 
-The goal of HPV vaccine is protection against dysplasia, rather than 
against a sexually transmitted infection.  
HPV vaccine is 
different from other 
vaccines 
-The concept that HPV vaccine is used to 
prevent dysplasia and cancer stands in 
contrast to all other vaccines where the goal 
is to prevent acute infections. 
-This point once more underscores the need 
to differentiate between individual vaccines 
when discussing the notion of “vaccine 
hesitancy”, particularly among patients who 
might not have categorical attitudes towards 
all vaccines.  
-This point is important also because, for 
example, not vaccinating against measles 
carries a considerable risk for the child to 
acquire measles, whereas not vaccinating 
against HPV carries little long-term risk, 
because most HPV infections are transient 
and can be prevented, at least partially, by 
other means (i.e., safe sex practices, fewer 
sexual partners, cervical cancer screening).  
-This is a point definitely worth emphasizing because it is crucial for 
understanding why HPV vaccine might be important and therefore 
crucial for vaccine counseling. 
-Emphasize that there is no need to use fear as a communication 
strategy in order to promote the HPV vaccine. 
-It is OK to state that, similarly, there is no need by vaccine skeptics to 
use fear (of serious side effects, e.g., multiple sclerosis) to discourage 
vaccine.  
Vaccination of boys 
and young men 
-The discussion of cancer at the oropharynx 
and anus is important. 
-This should be elaborated in order to address the prevalent notion 
that the HPV vaccine is only indicated for women.  
High cost of the 
vaccine 
-HPV vaccine is the most expensive, widely 
recommended vaccine.  
-The high vaccine cost puts a strain on 
already tight public health budgets, even in 
a rich country like Switzerland. 
-The HPV vaccine is very lucrative for 
vaccine manufacturers. 
-The financial aspects surrounding HPV vaccine should not be kept 
secret, as has been the case until now. This secrecy is a major driver of 
vaccine hesitancy 
-The high cost of HPV vaccines should be discussed appropriately. 
Please clarify whether taxpayer money is being used to subsidize the 
vaccine. 
HPV vaccine 
coverage of >70% 
may be sufficient to 
lead to herd 
protection in a 
given population 
-This is an important point. -Elaborate further with relevant references. 
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4. Discussion 
Our collaboration with six CAM-oriented physicians has shown three main results. First, the 
process of generating HPV vaccine review articles and communication tools in collaboration with 
CAM providers appears feasible and may represent an important novel approach to better 
addressing VH. Second, we have generated an inventory of HPV vaccine messaging 
recommendations that are likely, according to four CAM doctors, to be relevant and palatable to VH 
HCPs but that may improve vaccine counseling by all HCPs. As shown in the results section, the 
messaging recommendations that would likely appeal to VH HCPs and CAM provider audiences 
dealt with being sensitive to language use, particularly language perceived as overtly and uncritically 
“pro-vaccine”, precisions about safety and efficacy data, emphasizing vaccination as a choice in 
clinical communication, and the inclusion of detailed information about HPV infections and HPV 
vaccine specific information. Table 6 (below) summarizes the key strategies recommended by CAM 
doctors for vaccine communication that gets vaccine-skeptical HCP on board. Third, and perhaps 
most importantly, our collaboration with four reviewing CAM doctors was constructive and resulted 
in messaging that was largely in favor of vaccination. This stands in contrast to popular narratives 
which pigeonhole CAM users and providers as categorically anti-vaccine [12], or those who express 
skepticism towards vaccination as ‘opponents’ [37].  
Our collaborative approach is, to our knowledge, a first attempt of taking a CAM-inclusive 
rather than CAM-exclusive vaccine messaging approach. This may seem self-evident, but it goes 
beyond traditional top-down, knowledge deficit model efforts by (1) actively including VH HCPs in 
the target audience for HPV review articles, (2) listening to and engaging relevant stakeholders, (3) 
trying to understand the needs of the VH HCP audience, (4) targeting communication to those needs, 
and (5) designing culturally targeted interventions [38]. Thomson et al. point to the need to 
“understand and act upon the fact that there is no one-size fits all strategy to solve vaccine hesitancy 
and that collaborative efforts are needed and must be sustained over time” ([38], p. 6458). We were 
particularly impressed, despite initial skepticism on both sides, to be able to frame our reviews and 
communication tools in ways that were in line with official HPV vaccine recommendations, but also 
sensitive to providing HPV disease and vaccine information with nuanced language for issues where 
VH HCPs might have particular degrees of skepticism and concerns. Recognizing that language 
matters in healthcare [39,40], and that nuanced language choice can both empower and stigmatize in 
the oft-polarized discussions around vaccination, will be important for establishing meaningful 
dialogue in future efforts to address VH. 
The aim of our collaboration with four CAM doctors in the design of HPV vaccine review articles 
and communication tools [19,20] was to ensure that these materials would be read not only by HCPs 
already favorable to vaccination, but useful particularly to the additional target audience of VH 
HCPs. To our knowledge, a CAM-inclusive approach has not yet been used in creating vaccine 
messaging materials for use in clinical practice. Additionally, this collaboration offers an innovative 
approach seeking to address VH around HPV vaccine, which is the vaccine listed on the Swiss 
vaccination schedule that has attained the lowest coverage in Switzerland [27,28]. Importantly, WHO 
cited healthcare professionals as “the most trusted advisor[s] and influencer[s] of vaccination 
decisions” [1]. Oehler [41] recently echoed these statements in response to the recent global measles 
resurgence: “New tools are needed for physicians and healthcare providers to reverse this trend and 
regain our role as patient’s best advocates”. In our view, our review articles clearly benefited from 
CAM doctors’ emphasis on patient-oriented medicine and from their focus on building trusting 
relationships with patients and families, which have been shown as important considerations for VH 
patients.  
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Table 6. Key general strategies recommended by 4 CAM doctors in order to improve vaccine 
communication and to get vaccine-skeptical health care providers on board. 
• Generate review articles on vaccines that are written by practicing doctors 
o i.e., authors that are independent of the health authorities and the federal government’s vaccine commission 
• Consider that a significant proportion of health care providers are vaccine hesitant, not just patients. This is your 
target audience 
• Begin the articles by providing detailed background information on the infectious disease aimed to be prevented by 
vaccination 
o Only in a 2nd step talk about the safety and efficacy of the individual vaccine(s) available 
• Discuss immunity associated with natural infection and provide comparison with immunity associated with 
vaccination 
• Avoid overtly pro-vaccine language 
o Avoid categorically repeating that all vaccines are safe and effective 
o Rather, emphasize the importance of individual patients reaching their personal, individually selected health and prevention 
goals. Vaccination remains a free, individual choice in countries that have no vaccine mandates in place, such as Switzerland 
• Use precise and nuanced language 
o Avoid lumping all vaccines together. Very few patients are against “vaccination” in general 
o Clarify in each instance whether “protection” refers to protective antibody levels, prevention of persistent HPV infection, 
dysplasia, or cancer 
o Avoid stating that HPV vaccine protects against cancer before solid data is available 
o Speculation (on duration of protection after vaccination, on efficacy against cancer, etc.) is acceptable, but label it as such 
o For vaccines where herd immunity plays no or a limited role, avoid discussions of herd immunity and of a moral obligation to 
vaccinate 
• Take vaccine safety concerns seriously 
o Acknowledge the existence of rare cases of serious illnesses following vaccination 
o In a second step, mention robust, large scale epidemiological vaccine safety data 
• Discuss potential problems and side effects from the vaccination, discuss critical papers, alternatives and/or the 
potential consequences of vaccination and non-vaccination 
• Emphasize the importance of the provider investing time and effort in order for the patient to be able to reach an 
informed vaccination decision 
• Mention the price and financial implications of each vaccine 
o Be aware of one of the major determinants of vaccine hesitancy: the prevalent perception that the health authorities are 
collaborating with and/or influenced by vaccine manufacturers  
The work presented here suggests the feasibility of collaborative approaches that engage CAM 
providers, and we recommend such innovation to other researchers and for other health care issue 
and communication settings. For example, based on our productive cooperation, our research team 
is now conducting focus group discussions with CAM and biomedical providers in order to design 
vaccination communication interventions. We have now also successfully collaborated with the same 
CAM providers on other topics during the preparation of review articles for Swiss HCPs aiming at 
reducing antibiotic overuse in the setting of acute respiratory infections and asymptomatic 
bacteriuria and cystitis.  
On a larger scale, our ongoing National Research Program on vaccine hesitancy [13,14] has 
recruited a network of more than 150 medical professionals throughout Switzerland, including more 
than 40 CAM practitioners. Given the popularity and interest towards CAM of the Swiss population 
[21,22] and from pediatricians [26], the incorporation of CAM perspectives and engagement with 
practitioners of both CAM and biomedicine into vaccination communication strategies is, in our 
view, a feasible, innovative, and reasonable approach to addressing VH in the Swiss context.  
Our work has limitations. Even though the four collaborating CAM doctors were prominent 
CAM practitioners in their fields, they could not possibly represent the perspectives of all CAM 
providers in Switzerland, in particular the most hesitant providers. Rather, we took their 
recommendations by considering them as a sounding board for the creation of messaging that they 
felt would overcome the initial hurdle of rejection by VH HCPs and also gain traction within their 
various networks of CAM providers. However, we do not have data about the overall impact of the 
two HPV vaccine review articles among HCPs, nor do we have data about their influence on VH 
among HCPs. Such measurements go beyond the scope of this article.  
Additionally, we did not integrate all CAM doctor suggestions into the final manuscripts in an 
‘anything goes’ approach. Final decisions were negotiated internally with the conditions that we stay 
within the realms of evidence-based medicine, we adhere to official HPV vaccine guidelines, and that 
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we make note of the quality of available evidence we presented in the final articles. This was possible 
in the vast majority of instances. 
5. Conclusions 
In this article, we show that our approach to engaging with CAM providers is feasible and 
productive. We have provided an inside look into an innovative approach for drafting HPV vaccine 
review articles and communication tools which seem relevant to all providers, including potentially 
VH HCPs. Using nuanced communication suggested to us by four CAM doctors, we were able to 
develop an intervention approach with the explicit goal of addressing VH among physicians and 
patients by improving the factual and communicative quality of HPV vaccine information. By 
inviting CAM doctors as co-authors, we sent a symbolically strong message to practitioners of CAM 
in Switzerland, indicating that we recognize their important clinical and public health role in 
providing vaccine counseling, particularly to VH individuals [15,42], and that biomedicine can 
incorporate CAM vaccination perspectives into materials destined for all HCPs. Through such 
collaboration, we have shown how it is possible to work with individuals that popular narratives 
would have us believe to be ‘the opponent’ when it comes to VH [37]. Addressing VH in clinical 
practice can, and should, benefit from multiple perspectives and involve all culturally relevant and 
appropriate stakeholders while informing medical review articles and communication tools for 
HCPs.  
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